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Background. Altered mineral metabolism contributes to
bone disease, cardiovascular disease, and other clinical prob-
lems in patients with end-stage renal disease.
Methods. This study describes the recent status, significant
predictors, and potential consequences of abnormal mineral
metabolism in representative groups of hemodialysis facilities
(N = 307) and patients (N = 17,236) participating in the Dialysis
Outcomes and Practice Patterns Study (DOPPS) in the United
States, Europe, and Japan from 1996 to 2001.
Results. Many patients fell out of the recommended guide-
line range for serum concentrations of phosphorus (8% of
patients below lower target range, 52% of patients above up-
per target range), albumin-corrected calcium (9% below, 50%
above), calcium-phosphorus product (44% above), and intact
PTH (51% below, 27% above). All-cause mortality was signifi-
cantly and independently associated with serum concentrations
of phosphorus (RR 1.04 per 1 mg/dL, P = 0.0003), calcium (RR
1.10 per 1 mg/dL, P < 0.0001), calcium-phosphorus product
(RR 1.02 per 5 mg2/dL2, P = 0.0001), PTH (1.01 per 100 pg/dL,
P = 0.04), and dialysate calcium (RR 1.13 per 1 mEq/L, P =
0.01). Cardiovascular mortality was significantly associated with
the serum concentrations of phosphorus (RR 1.09, P < 0.0001),
calcium (RR 1.14, P < 0.0001), calcium-phosphorus product
(RR 1.05, P < 0.0001), and PTH (RR 1.02, P = 0.03). The
adjusted rate of parathyroidectomy varied 4-fold across the
DOPPS countries, and was significantly associated with baseline
concentrations of phosphorus (RR 1.17, P < 0.0001), calcium
(RR 1.58, P < 0.0001), calcium-phosphorus product (RR 1.11,
P < 0.0001), PTH (RR 1.07, P < 0.0001), and dialysate calcium
concentration (RR 0.57, P = 0.03). Overall, 52% of patients re-
ceived some form of vitamin D therapy, with parenteral forms
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almost exclusively restricted to the United States. Vitamin D
was potentially underused in up to 34% of patients with high
PTH, and overused in up to 46% of patients with low PTH.
Phosphorus binders (mostly calcium salts during the study pe-
riod) were used by 81% of patients, with potential overuse in up
to 77% patients with low serum phosphorus concentration, and
potential underuse in up to 18% of patients with a high serum
phosphorus concentration.
Conclusion. This study expands our understanding of the re-
lationship between altered mineral metabolism and outcomes
and identifies several potential opportunities for improved prac-
tice in this area.
End-stage renal disease (ESRD) is accompanied by
profound changes in mineral metabolism. The labora-
tory manifestations include hypocalcemia, hyperphos-
phatemia, hypovitaminosis D, and hyperparathyroidism.
Abnormal mineral metabolism leads to metabolic bone
disease [1] and contributes to other clinical problems,
such as muscle and joint disease, anemia, neuropa-
thy, and impotence. The complex relationship between
metabolic abnormalities and clinical disease confounds
efforts to prioritize corrective interventions. Evidence-
based guidelines have been developed to assist with treat-
ment decisions. These guidelines propose target ranges
for such indicators of mineral metabolism as serum cal-
cium, phosphorus, and parathyroid hormone (PTH) con-
centrations. However, the evolving guidelines are often
based on incomplete information. Although bone disease
has been the traditional focus of concern, recent stud-
ies highlight the importance of other outcomes, particu-
larly vascular disease and mortality. This paper describes
the associations between mineral metabolic abnormali-
ties and mortality for hemodialysis patients in 7 coun-
tries participating in the Dialysis Outcomes and Practice
Patterns Study (DOPPS).
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METHODS
The study was done as part of the DOPPS, an inter-
national, observational study of hemodialysis practices
and outcomes in countries with large populations of dial-
ysis patients: France, Germany, Italy, Japan, Spain, the
United Kingdom, and the United States. The study design
has been described previously [2]. Institutional Review
Board approval and patient informed consent were ob-
tained as required in each country. A representative sam-
ple of hemodialysis facilities was selected in each country
(France, Germany, Italy, Spain, and the UK, N = 20 each;
Japan, N = 65; U.S., N = 142). Patients were entered into
the study from 1996 to 2001 in the U.S., from 1998 to 2000
in Europe, and from 1999 to 2000 in Japan. A random
sample of patients was selected from each facility at the
start of the study, representing a prevalent cross-section
(N = 8615). As patients departed during the study (due
to death, transplantation, withdrawal, transfer, or dialysis
modality change), replacement patients were randomly
selected (N = 8621) from the pool of patients new to the
facility since the last sample selection. The initial cross-
section sample of prevalent patients was used to describe
patient characteristics, such as the distribution of labora-
tory values. The entire sample of 17,236 patients was used
for statistical modeling.
Clinical data were abstracted from the medical record
for each study patient using standardized questionnaires.
Dialysis facility personnel, usually a dialysis nurse, per-
formed data abstraction. Follow-up data were obtained
at approximately 4-month intervals. The major outcomes
for this study were all-cause mortality, cardiovascular
mortality, and parathyroidectomy (PTX). Cardiovascular
mortality included deaths attributed to acute myocardial
infarction, atherosclerotic heart disease, cardiac arrhyth-
mia, and cardiac arrest (causes unknown). The major
predictor variables were baseline patient characteris-
tics, baseline laboratory markers of mineral metabolism,
and modifiable practice patterns related to management
of mineral metabolism (vitamin D, phosphorus binder,
dialysate calcium concentration). Only PTH concentra-
tion measurements obtained by way of intact molecule
assay were used in these analyses.
Standard descriptive statistics were used to describe
the baseline state of mineral metabolism at the patient
level. Logistic regression models, accounting for facil-
ity clustering effects, were used to determine the pre-
dictors of laboratory values that fell out of the guideline
range. The Cox proportional hazards model was used to
study associations between mortality (all-cause and car-
diovascular) and markers of mineral metabolism. Cox
survival models were stratified by country and adjusted
for age, gender, race, duration of ESRD, single-pool Kt/V,
serum albumin, hemoglobin, dialysate calcium concen-
tration, and 14 summary comorbid conditions present
at study entry (coronary artery disease, congestive heart
Table 1. Characteristics of study sample
Frequency (%) or mean
Initial Replacement All
cross-section patients patients
Demographics (N = 8615) (N = 8621) (N = 17,236)
Age mean years 59.9 61.1 60.5
Duration of ESRD 4.9 1.2 3.1
mean years
Male 56.8 57.9 57.4
Black 17.7 20.8 19.2
Cause of ESRD
Diabetes 26.9 36.8 31.6
Hypertension 18.4 23.8 21.0
Glomerulonephritis 30.1 17.1 23.8
Other 24.7 22.3 23.5
Coronary heart disease 36.0 40.5 38.3
Congestive heart failure 29.6 38.0 33.8
Other cardiovascular disease 33.2 28.4 30.8
Hypertension 73.2 77.5 75.3
Cerebrovascular disease 15.5 16.7 16.1
Peripheral vascular disease 21.3 22.8 22.1
Diabetes 33.0 42.6 37.8
Lung disease 9.4 12.0 10.7
Cancer, other than skin 8.4 11.3 9.8
HIV/AIDS 0.6 1.0 0.8
Gastrointestinal bleeding 6.9 7.1 7.0
Neurologic disease 8.4 8.4 8.4
Psychiatric disorder 18.9 22.9 20.9
Recurrent cellulitis 7.5 7.0 7.3
failure, other cardiac disease, hypertension, cerebrovas-
cular disease, peripheral vascular disease, diabetes, lung
disease, cancer (excluding skin), HIV/AIDS, gastroin-
testinal bleeding, neurologic disease, psychiatric disease,
and recurrent cellulitis). In addition, models were simul-
taneously adjusted for laboratory measures related to
mineral metabolism including serum concentrations of
phosphorus, calcium, and intact PTH. Prospective PTX
models were adjusted for country, age, gender, race, dura-
tion of ESRD, PTH, serum calcium, serum phosphorus,
and prior PTX. Survival models accounted for facility
clustering effects using robust standard estimates based
on the sandwich estimator. Statistical analyses were per-
formed using SAS software, version 8.2 (SAS Institute;
Cary, NC, USA).
RESULTS
Characteristics of study sample
Table 1 displays the characteristics of the initial preva-
lent cohort, the replacement patient cohort, and the over-
all sample. By design, the replacement patients were
enriched with new ESRD patients, as illustrated by fewer
prior years of ESRD. The replacement patient group was
older and had a higher prevalence of comorbid condi-
tions, particularly diabetes mellitus and cardiovascular
diseases. The study cohort yielded 4565 deaths (crude
rate=18.3/100 patient-years), 2278 cardiovascular deaths
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Table 2. Parathyroidectomy (PTX) by country at baseline and prospectively
Baseline Follow-up
Country Prevalence (%) AOR (P value) Number Incidence (/100 pt-yrs) RR (P value)
France (N = 981) 14.3 2.2 (<0.0001) 20 1.8 3.76 (<0.0001)
Germany (N = 908) 6.0 1.5 (0.11) 11 1.0 3.19 (0.02)
Italy (N = 869) 5.0 0.7 (0.25) 10 0.9 2.16 (0.08)
Japan (N = 2784) 4.1 0.4 (<0.0001) 26 0.6 1.07 (0.80)
Spain (N = 936) 5.7 1.1 (0.75) 16 1.5 4.06 (<0.0001)
UK (N = 897) 9.2 2.5 (<0.0001) 12 1.5 3.18 (0.01)
U.S. (N = 9861) 4.0 1.0 (ref) 70 0.5 1.0 (ref)
AOR, adjusted odds ratio of having had a PTX (yes vs. no) prior to study entry; RR, relative risk of having a PTX during study follow-up. Adjustments for both
models included age, gender, race, and duration of ESRD; the follow-up model was also adjusted for prior PTX.
Table 3. Descriptive statistics of laboratory values related to mineral metabolism in an initial cross-section of hemodialysis patients
% of patients
Recommended Below lower Above upper
Serum value rangea Mean (SD) Median range limit range limit
Phosphorus (N = 8265) 3.5–5.5 mg/dL 5.8 (1.8) 5.6 7.6 51.6
Japan (N = 2132) 5.8 (1.6) 5.7 5.8 53.6
Europe (N = 2525) 5.7 (1.9) 5.5 10.1 49.4
U.S. (N = 3608) 5.9 (1.9) 5.6 6.8 51.9
Albumin-corrected calcium (N = 6898) 8.4–9.5 mg/dL 9.6 (1.0) 9.5 9.3 50.2
Japan (N = 1617) 9.4 (1.0) 9.4 12.2 45.2
Europe (N = 1720) 9.7 (0.9) 9.6 7.2 55.6
U.S. (N = 3561) 9.6 (1.0) 9.5 9.1 49.9
Ca-P product (N = 8070) <55 mg2/dL2 54 (17) 53 NA 43.5
Japan (N = 2131) 54 (16) 52 NA 43.2
Europe (N = 2337) 54 (19) 53 NA 43.2
U.S. (N = 3602) 54 (17) 53 NA 43.8
PTH (N = 5240) 150–300 pg/mL 274 (400) 144 51.1 26.7
Japan (N = 1142) 196 (241) 111 58.6 19.0
Europe (N = 1716) 269 (365) 149 50.1 26.9
U.S. (N = 2382) 316 (473) 158 48.2 30.3
Initial cross-section taken at study start (1996 in the U.S., 1998 in Europe, 1999 in Japan).
aAccording to NKF K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease [5].
(crude rate = 10.0/100 patient-years) and 165 parathy-
roidectomies (crude rate = 0.7/100 patient-years). Coun-
try differences in mortality rates and comorbidities in the
DOPPS have been described previously [3, 4]. PTX prac-
tice varied by country, as measured by the baseline preva-
lence of prior PTX (Table 2). Similarly, the prospective
rate of PTX during follow-up varied 4-fold across coun-
tries (Table 2).
Phosphorus
The serum phosphorus concentration and its substan-
tial deviation from guidelines among the prevalent pa-
tient sample are shown in Table 3. Only 41% of this
cross-section of patients was found to have a serum phos-
phorus concentration within the range recommended by
U.S. (NKF K/DOQITM) [5] and European (EBPG) [6]
guidelines. More than half the patients exceeded the rec-
ommended level of 3.5 to 5.5 mg/dL. Table 4 shows that a
serum phosphorus below the target range (<3.5 mg/dL)
was significantly more likely in patients with low serum
albumin concentration, older age, and higher dialysate
calcium. A serum phosphorus concentration above the
target range (>5.5 mg/dL) was inversely associated with
age, black race, dialysis dose, and treatment in Italy; it was
directly associated with the serum albumin concentration
and treatment in Germany. All-cause and cardiovascu-
lar mortality were significantly associated with the serum
phosphorus concentration (Table 5). Figure 1 shows that
the relationship between all-cause mortality and serum
phosphorus was bimodal with significantly higher risk
of death for patients with serum phosphorus levels be-
low 3.5 mg/dL (affecting 10% of patients) and above
6.5 mg/dL (affecting 29% of patients). The relative rate
of new PTX was also associated with higher serum phos-
phorus concentration (Table 5).
Calcium
Table 3 shows the distribution of the serum to-
tal calcium concentration (corrected for serum albu-
min concentration) relative to recent guidelines. The
serum calcium concentration was below the lower rec-
ommended range limit (<8.4 mg/dL) in 9.3% of patients,
and above the upper range limit (>9.5 mg/dL) in 50% of
patients. A serum calcium concentration below the tar-
get range was significantly more likely in males and in pa-
tients with higher serum albumin concentration (Table 4).
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Table 4. Clinical and laboratory characteristics significantly associated with abnormal laboratory values
Lab abnormality Inverse associations (less likely) Direct associations (more likely)
Low serum phosphorus (<3.5 mg/dL) Serum albumin (0.64 per 1 g/dL) Age (1.01 per year)
Dialysate Ca (1.40 per 1 mEq/L)
Treated in UK (1.45)
High serum phosphorus (>5.5 mg/dL) Age (0.98 per year) Serum albumin (1.26 per 1 g/dL)
Black race (0.75) Treated in Germany (1.66)
spKt/V (0.77 per 1 unit)
Treated in Italy (0.65)
Low albumin-corrected calcium (<8.4 mg/dL) Age (0.99 per year) Male sex (1.25)
Duration of ESRD (0.96 per year) Serum albumin (1.83 per 1 g/dL)
Hemoglobin (0.85 per 1 g/dL)
Treated in UK (0.58)
High albumin-corrected calcium (>9.5 mg/dL) Male sex (0.74) Duration of ESRD (1.07 per year)
Diabetes (0.77) Hemoglobin (1.13 per 1 g/dL)
Serum albumin (0.63 per 1 g/dL) spKt/V (1.40 per 1 unit)
Other cardiac disease (1.15)
Recurrent cellulitis (1.27)
Treated in:
Spain (1.54)
UK (2.04)
Low PTH (<150 pg/mL) Black race (0.64) Dialysate Ca (1.31 per 1 mEq/L)
Vitamin D therapy (0.82)
High PTH (>300 pg/mL) Age (0.99 per year) Black race (1.45)
Male sex (0.85) Duration of ESRD (1.04 per year)
Hemoglobin (0.93 per 1 g/dL) Vitamin D therapy (1.31)
spKt/V (0.56 per 1 unit)
Diabetes (0.65)
HIV (0.33)
Treated in Japan (0.37)
Adjusted odds ratios (AOR) given in parentheses. Models adjusted for age, gender, race, duration of ESRD, vitamin D use, dialysate calcium concentration,
hemoglobin, albumin, Kt/V, country, and 14 summary comorbid conditions. Reference group = lab values in target range [5, 6]. All associations listed are significant at
P < 0.01 level.
Table 5. Association between study outcomes (all-cause mortality, cardiovascular mortality, and parathyroidectomy) and markers of mineral
metabolism
RR (95% CI) P value
Baseline lab measure All-cause mortalitya Cardiovascular mortalitya Risk of new parathyroidectomyb
Phosphorus (per 1mg/dL) 1.04 1.09 1.17
(1.02–1.06) (1.05–1.12) (1.09–1.25)
0.0003 <0.0001 <0.0001
Albumin-corrected calcium (per 1 mg/dL) 1.10 1.14 1.58
(1.06–1.15) (1.07–1.21) (1.35–1.85)
<0.0001 <0.0001 <0.0001
Calcium-phosphorus product (per 5 mg2/dL2) 1.02 1.05 1.11
(1.02–1.03) (1.05–1.05) (1.10–1.12)
0.0001 <0.0001 <0.0001
PTH (per 100 pg/mL) 1.01 1.02 1.07
(1.00–1.02) (1.00–1.03) (1.05–1.09)
0.04 0.03 <0.0001
Dialysate calcium (per 1 mEq/L) 1.13 1.09 0.57
(1.03–1.25) (0.92–1.30) (0.35–0.95)
0.01 0.30 0.03
All models were adjusted for PTH, dialysate calcium, and either calcium and phosphorus as two independent variables or calcium-phosphorus product as one
independent variable.
aStratified by country and adjusted for age, gender, race, duration of ESRD, hemoglobin, albumin, Kt/V, and 14 summary comorbid conditions.
bStratified by country and adjusted for age, gender, race, duration of ESRD, hemoglobin, albumin, Kt/V, and prior parathyroidectomy.
A serum calcium concentration below the target range
was inversely associated with age, duration of ESRD,
hemoglobin concentration, and treatment in the UK.
A serum calcium concentration above the target range
was significantly associated with clinical factors shown
in Table 4. All-cause and cardiovascular mortality were
significantly associated with the serum calcium concen-
tration (Table 5, Fig. 2). Serum calcium concentrations
below 7.8 mg/dL were associated with significantly lower
mortality risk (Fig. 2). The risk of new PTX was strongly
associated with the baseline serum calcium concentration
(Table 5).
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Fig. 1. Association between all-cause mortality and serum phosphorus concentration. Stratified by country and adjusted for serum concentrations
of calcium and PTH, dialysate calcium concentration, age, gender, race, duration of ESRD, hemoglobin, albumin, Kt/V, and 14 summary comorbid
conditions. ∗P < 0.05; ∗∗P < 0.01; †P < 0.001; ‡P < 0.0001.
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Fig. 2. Association between all-cause mortality and the serum concentration of calcium (corrected for albumin concentration). Stratified by country
and adjusted for serum concentrations of phosphorus and PTH, dialysate calcium concentration, age, gender, race, duration of ESRD, hemoglobin,
albumin, Kt/V, and 14 summary comorbid conditions. ∗P < 0.05; ∗∗P < 0.01; †P < 0.001; ‡P < 0.0001.
Calcium-phosphorus product
The average calcium-phosphorus product (not cor-
rected for albumin) was 54 mg2/dL2, with approximately
44% of patients exceeding the recommended upper limit
of 55 mg2/dL2. All-cause mortality, cardiovascular mor-
tality, and parathyroidectomy risk were significantly as-
sociated with the calcium-phosphorus product (Table 5).
Categorical analysis revealed a significantly increased
mortality risk above a calcium-phosphorus product of ap-
proximately 65 mg2/dL2 (Fig. 3).
Parathyroid hormone
The prevalent patient cohort exhibited large variation
in the serum intact PTH concentration, as illustrated by
the large standard deviation (Table 3). The optimal range
for PTH is considered to be 150 to 300 pg/mL [5, 6]. The
PTH concentration was below 150 pg/mL in 51% of pa-
tients and above 300 pg/mL in 27% of patients. Table 4
shows that low PTH (<150 pg/dL) was directly associ-
ated with the dialysate calcium concentration and in-
versely associated with black race and vitamin D therapy.
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Fig. 3. Association between all-cause mor-
tality and serum calcium-phosphorus prod-
uct. Stratified by country and adjusted for
serum concentration of PTH, dialysate cal-
cium concentration, age, gender, race, dura-
tion of ESRD, hemoglobin, albumin, Kt/V,
and 14 summary comorbid conditions.∗P <
0.05; ∗∗P < 0.01; †P < 0.001; ‡P < 0.0001.
Table 6. Facility distribution of practice patterns related to mineral metabolism (initial cross section)
Facility distribution by percentile
Practice % Patients 25th 50th 75th
Vitamin D therapy (N1 = 8615; N2 = 307) 52.2 36.8 51.4 66.7
Japan (N1 = 2169; N2 = 64) 62.9 50.0 61.3 79.5
Europe (N1 = 2590; N2 = 101) 46.5 30.8 46.2 59.1
U.S. (N1 = 3856; N2 = 142) 50.0 36.0 50.0 65.5
Phosphorus binder (N1 = 8615; N2 = 307) 81.1 76.7 86.2 92.6
Japan (N1 = 2169; N2 = 64) 82.0 75.9 88.5 93.8
Europe (N1 = 2590; N2 = 101) 77.3 70.2 81.4 91.8
U.S. (N1 = 3856; N2 = 142) 83.1 80.0 87.5 92.3
Low dialysate calcium (≤2.5 mEq/L) (N = 7629; N = 307) 40.5 0.0 24.3 96.3
Japan (N = 2123; N = 64) 19.8 0.0 0.0 9.1
Europe (N = 1839; N = 101) 23.9 0.0 4.5 42.3
U.S. (N = 3,667; N = 142) 64.1 25.6 89.4 100.0
N1 = patients; N2 = facilities. Initial cross-section taken at study start (1996 in the U.S., 1998 in Europe, 1999 in Japan.
In contrast, high PTH (>300 pg/dL) was directly associ-
ated with black race, duration of ESRD, and vitamin D
therapy, and was inversely associated with age, male sex,
hemoglobin, dialysis dose, diabetes, HIV, and treatment
in Japan. All-cause and cardiovascular mortality were as-
sociated with serum PTH concentration (Table 5). Not
surprisingly, the risk of new PTX was also strongly pre-
dicted by the baseline PTH concentration (Table 5).
Vitamin D therapy
Overall, 52% of point-prevalent patients were treated
with some form of vitamin D therapy (Table 6). The use of
vitamin D therapy varied among facilities, ranging from
0% to 100%. At the 25th facility percentile, 37% of pa-
tients received vitamin D, compared to 67% of patients at
the 75th facility percentile. Parenteral vitamin D therapy
was largely restricted to U.S. facilities (44% in U.S., 4%
in Europe, and <1% in Japan). Vitamin D therapy was
given to 46% of patients with a low PTH concentration
and to 65% of patients with a high PTH concentration
(Table 7). After excluding patients whose serum phos-
phorus and calcium levels exceeded the guideline limit,
vitamin D therapy was used in only 69% of patients with
high PTH concentrations. Even when using less stringent
PTH target values, vitamin D was used by 46% to 50% of
patients with a PTH <100 pg/mL and by 66% to 74% of
patients with a PTH concentration >400 pg/mL (Table 7).
Future PTX was significantly less likely among patients
who were receiving vitamin D therapy at baseline (OR
0.62, P = 0.01). Vitamin D therapy was not significantly
associated with mortality.
Phosphorus binder therapy
Phosphorus binders were taken by 81% of the patient
sample (Table 6). Use of phosphorus binders varied mod-
estly by facility. The specific binding agents in use during
the time of the study were calcium carbonate (53%), cal-
cium acetate (26%), aluminum salts (6%), calcium cit-
rate (1%), and magnesium salts (1.5%). Sevelamer was
used by only 0.1% of patients, as it only became avail-
able at the end of the study observation period. Phospho-
rus binder therapy was administered to approximately
77% of patients with a low serum phosphorus concen-
tration and to 83% of patients with a high serum phos-
phorus concentration (Table 7). The same percentage
of patients (83%) received phosphorus binders whether
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Table 7. Use of specific therapies by laboratory guideline range (initial cross-section)
Guideline range (% of patients)
Below Within Above Below Within Above
Serum PTH <150 150–300 >300 <100 100–400 >400
(N = 2677) (N = 1164) (N = 1399) (N = 2018) (N = 2222) (N = 1000)
Patients receiving vitamin D preparation 46.1 53.1 65.7 46.0 53.4 65.7
Patients with Ca <9.5 and P <5.5 receiving 47.2 53.8 69.1 49.5 51.1 73.5
vitamin D preparation
Serum phosphorus <3.5 3.5–5.5 >5.5 <3.0 3.0–6.0 >6.0
(N = 621) (N = 3340) (N = 4221) (N = 321) (N = 4618) (N = 3243)
Patients receiving phosphorus binder therapy 76.8 83.3 83.4 75.1 82.7 83.9
Albumin-corrected calcium <8.4 8.4–9.5 >9.5 <7.9 7.9–10.0 >10.0
(N = 644) (N = 2792) (N = 3462) (N = 243) (N = 4647) (N = 2008)
Patients with dialysate Ca ≤2.5 38.2 44.1 46.5 39.5 44.0 47.2
Initial cross-section taken at study start (1996 in the US, 1998 in Europe, 1999 in Japan).
serum phosphorus was high or within range. Also, sim-
ilar percentages of patients were potentially overusing
or underusing phosphorus binders when the analysis was
conducted using less stringent threshold concentrations
(<3.0 mg/dL, >6.0 mg/dL).
Dialysate calcium concentration
The K/DOQI guidelines recommend a dialysate con-
centration of 2.5 mEq/L, while the EBPG does not make a
specific recommendation. The average dialysate calcium
concentration was 2.9 mEq/L, with almost 60% of pa-
tients exceeding the K/DOQI recommendation (Table 6).
The recommended low calcium dialysate was employed
more often in U.S. facilities than in Europe and Japan.
Table 7 shows that a low dialysate calcium concentra-
tion (≤2.5 mEq/L) was used for 38% of patients with a
low serum calcium concentration (<8.4 mg/dL) and for
47% of patients with a high serum calcium concentration
(>9.5 mg/dL). Similar use patterns were seen for patients
at more extreme cut-points of serum calcium. All-cause
(but not cardiovascular) mortality risk was significantly
associated with higher dialysate calcium concentration,
adjusted for the serum concentrations of calcium and
phosphorus (Table 5). The risk of PTX was inversely as-
sociated with the dialysate calcium concentration.
DISCUSSION
The topic of mineral metabolism in renal failure has
traditionally focused on bone health [1]. However, there
is growing evidence that factors involved in mineral
metabolism are associated with other disease processes.
Specifically, a strong association between mortality and
markers of mineral metabolism has been reported in sev-
eral observational studies [7, 8]. Altered levels of serum
calcium, phosphorus, and calcium-phosphorus product
influence the occurrence and rate of soft tissue and, par-
ticularly, vascular calcification (mineralization) [9, 10].
Vascular mineralization probably contributes to vascu-
lar occlusive disease, including the coronary, peripheral,
and cerebral circulations [11]. These findings reveal the
potential for optimal mineral metabolism management
to advance both bone and vascular health of dialysis pa-
tients [12]. Guidelines have recently been promulgated
[5, 6] based on the reported association of cardiovascu-
lar [13, 14] and skeletal consequences of altered mineral
metabolism.
The present study provides a useful measure of how
closely the new EBPG and K/DOQI mineral metabolism
guidelines were met during 1996 to 2001, prior to publica-
tion of the guidelines in 2002 and 2003. The study provides
a benchmark for evaluating practice improvements fol-
lowing dissemination of the new guidelines. The DOPPS
is particularly well suited to analyze guideline compliance
because it involves representative samples of hemodial-
ysis facilities and patients from 7 countries with large
populations of hemodialysis patients. The characteristics
of DOPPS patients closely match other source reports
from these same countries (Table 1) [15]. Furthermore,
this study adds to the body of observational evidence
concerning the relationship between patient survival and
mineral metabolism indicators and practices. PTX was
also studied as an outcome measure of an extreme and
potentially avoidable means of managing abnormal min-
eral metabolism.
Most patients studied in the 1996 to 1999 initial cross-
section fell outside of the recommended guideline val-
ues for phosphorus, calcium, and PTH, and nearly 44%
of patients exceeded the recommended upper range for
calcium-phosphorus product (Table 3). These findings re-
veal clear opportunities for improvement in patient care
and potentially improved outcomes.
This study also expands our understanding of the re-
lationship between altered mineral metabolism and out-
comes. As noted in other studies, high levels of serum
calcium, serum phosphorus [8], calcium-phosphorus
product [8], and PTH are associated with increased pa-
tient mortality (Table 5, Figs. 1 to 3). Our results generally
affirm the EBPG and K/DOQI guideline limits for these
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lab values. In addition, these factors are also associated
with a higher risk of subsequent PTX (Table 5). Cardio-
vascular mortality risk tended to be larger than all-cause
mortality risk, consistent with a potential pathogenic
pathway involving vascular mineral deposition. We found
increased mortality at lower concentrations of phospho-
rus (Fig. 1), perhaps due to nutritional deficiency that
was not adjusted for in the statistical models. We also
found decreased mortality at lower concentrations of
serum calcium (Fig. 2), in apparent contrast to at least
one prior study showing increased mortality [16]. Broader
adjustment for serum phosphorus, PTH, comorbidities,
and use of albumin-corrected calcium (recommended by
K/DOQI and EBPG) may explain this difference.
Parathyroid hormone plays a central role in min-
eral metabolism, especially bone health. High- and low-
turnover bone disease have been attributed to high and
low PTH concentrations, respectively [1]. Despite the tra-
ditional focus on hyperparathyroidism in renal failure,
it is noteworthy that low PTH concentrations were re-
ported for the majority of hemodialysis patients in this
study (Table 3). PTH concentrations below and above the
K/DOQI guideline levels were significantly associated
with age, gender, race, duration of ESRD, and several co-
morbid conditions (Table 4). Our study agrees with oth-
ers in finding that black patients were more likely to have
high PTH levels and less likely to have low PTH levels
[17, 18]. The association with ESRD duration is a proba-
ble consequence of chronic parathyroid gland stimulation
and hyperplasia. A PTH concentration below the guide-
line limit was directly associated with the dialysate cal-
cium concentration, suggesting oversuppression of PTH
that could be modified by choice of dialysate composi-
tion. Similarly, PTH concentration above the guideline
limit was inversely associated (approaching significance
at P = 0.053) with the dialysate calcium concentration,
suggesting a potentially modifiable practice that results in
excessive PTH stimulation. In contrast, low and high PTH
were negatively and positively associated, respectively,
with vitamin D therapy, suggesting the general appro-
priateness of prescribing vitamin D in response to PTH
level.
PTX is one therapeutic option for management of ad-
vanced hyperparathyroidism. We found large variation
among countries in the use of this operation, both at
baseline and during the course of the study (Table 2).
Although PTX was too infrequent to characterize as a
facility practice pattern, the large variation across coun-
tries suggests inconsistent indications and thresholds for
parathyroid surgery. Variability of this magnitude argues
for best-practice guidelines and clinical trials. Notwith-
standing large variability in the use of the procedure, the
risk of PTX was strongly associated with baseline labora-
tory values, including concentrations of serum phospho-
rus, calcium, and PTH (Table 5).
Several other treatments are available to manage min-
eral metabolism in dialysis patients, including vitamin D
analogs and phosphorus binders. The use of vitamin D
showed large variation across facilities (67% of patients
at the 75th facility percentile vs. 37% at the 25th facil-
ity percentile) and countries (Table 6). The use of par-
enteral vitamin D preparations was mainly restricted to
the U.S., probably due to Medicare reimbursement poli-
cies that only cover injectable medications. Considerably
less variability was seen in the use of phosphorus binders
across facilities (93% of patients at the 75th facility per-
centile vs. 77% at the 25th facility percentile) and coun-
tries (Table 6).
Overall, we found suggestive evidence for inappro-
priate use of vitamin D and phosphorus binder therapy
(Table 7). Specifically, almost half the patients with low
PTH were receiving vitamin D, despite apparent over-
suppression by current standards. In contrast, less than
two thirds of patients with high PTH received vitamin D
therapy. Vitamin D was also underused among patients
with high PTH who had their serum calcium and phos-
phorus concentrations within the target range. In other
words, hyperparathyroidism was untreated in over 30%
of patients who lacked an apparent contraindication to vi-
tamin D therapy. Conclusions about the appropriateness
of vitamin D therapy may be questionable for patients
with PTH values that are only slightly outside the tar-
get range. However, we found relatively high vitamin D
use even among patients with a PTH concentration <100
pg/mL, and relatively low use among patients with a PTH
concentration above 400 pg/mL (Table 7). In a similar
fashion, the study reveals a potential pattern of overuse of
phosphorus binders among patients with low serum phos-
phorus concentration of less than 3.5 mg/dL (77% were
treated), and underuse of phosphorus binders among pa-
tients with serum phosphorus concentration above 5.5
mg/dL (almost 17% were untreated). These estimates
may overstate the problems somewhat, as they are based
on single laboratory values and physicians may be adjust-
ing therapy according to the results. However, it is notable
that the use of phosphorus binders was very similar at less
stringent levels of serum phosphorus (<3.0 mg/dL and
>6.0 mg/dL, Table 7).
The dialysate calcium concentration varied by conti-
nent (Table 6). Overall, only 47% of patients with a high
serum concentration of calcium were dialyzed with a low
calcium bath (Table 7), indicating large opportunities for
improved management of the serum calcium concentra-
tion. Dialysate calcium use was very similar for patients
at more extreme levels of serum calcium (<7.9 mg/dL
and >10.0 mg/dL, Table 7), arguing against overstated
usage patterns due to patients who fell just slightly out
of the target range. Mortality risk was significantly as-
sociated with the higher dialysate calcium concentra-
tion, independent of the effects of serum calcium and
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phosphorus (Table 5). The mechanism for the indepen-
dent association between mortality and dialysate calcium
is not known, and the finding should be confirmed in
other studies. In contrast to mortality, PTX risk was un-
derstandably lower in patients treated with higher con-
centrations of dialysate calcium (Table 5). We suggest that
the potential mortality risk outweighs the PTX risk, sup-
porting a general recommendation for use of low calcium
dialysate. These findings come from a time when calcium
salts constituted the major type of phosphorus binder,
and before the availability of calcium- and aluminum-
free binders.
Potential limitations of this observational study include
inaccuracies in reporting. Data inaccuracies and noise
usually lead to underestimation of associations, so that
negative findings may be unreliable. However, it is worth
noting that statistical stratification across DOPPS coun-
tries indicates that the observed associations are present
in most countries.
CONCLUSION
The internationally representative DOPPS cohort
reveals that laboratory values related to mineral
metabolism fall outside the recommended range for
the majority of hemodialysis patients. Mortality and
PTX risks are strongly associated with altered mineral
metabolism laboratory values. Improvements may be
possible with modifications in the use of vitamin D prepa-
rations, phosphorus binders, and dialysate calcium con-
centrations.
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